Some Observations on the Collection of Medical Event Data

Abstract

A review of the philosophy, strategies, and methods for the collection of medical event (ME) information in clinical trials sponsored by the Research and Development Division of The Upjohn Company is presented. Goals for collection of ME information for Phase I, II, and III trials are reviewed. Case report form and terminology issues are discussed, with particular emphasis placed on procedures that avoid premature decisions on ME causality and incomplete reporting of events. Procedures for separating the seriousness from the intensity of the MEs are reviewed. Analysis issues are considered insofar as they impact on data collection procedures and goals. Recommendations are made with respect to protocol content, data collection forms, and related analysis issues.

Keywords

Forms design Terminology Causality Reporting barriers Intensity/gravity

Get full access to this article

View all access options for this article.

References

Idanpaan-Heikkila

: A Review of Safety Information Obtained from Phases I-II and Phase III Clinical Investigations of Sixteen Selected Drugs. FDA. Office of New Drug Evaluation, 1983.

Lasagna

: Techniques for ADR Reporting. Delect Prevent Adverse Drug React 1984; pp 146–151.

Downing

Rickels

Meyers

: Side reactions in neurotics: I. A comparison of two methods of assessment. J Clin Pharmacol 1970: pp 289–297.

Huskisson

Wojtulewski

: Measurement of side effects of drugs. Br Med J 1974;2:698–699.

Louik

Lacouture

Mitchell

: A study of adverse reaction algorithms in a drug surveillance program. J Clin Pharmacol Ther 1985;28:183–187.